On Apr. 21, 2020, Vaxart announced it had obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose. Vaxart is focused on vaccine candidates that can generate mucosal immune responses in addition to serum antibody responses.